For the roughly 70% of people who regain weight after stopping drugs like Ozempic or Wegovy, science has a new, slightly medieval-sounding proposal: a controlled gut burn. Research presented at Digestive Disease Week® (DDW) 2026 suggests a minimally invasive outpatient procedure called duodenal mucosal resurfacing might help maintain that hard-won weight loss without lifelong medication dependency.

Lead author Dr. Shelby Sullivan of Dartmouth Health noted the obvious problem: "As effective as GLP-1 medications are, many people stop taking them because of cost, side effects or simply not wanting to take a drug long-term." The subsequent weight regain, she points out, is a "huge unmet need." The proposed solution involves an endoscope and some heat, targeting the duodenum - the first section of the small intestine.

The procedure ablates, or burns, the damaged inner lining of the duodenum to encourage the growth of new, healthier tissue. The theory, being tested in the ongoing REMAIN-1 trial, is that this 'resurfacing' triggers a lasting metabolic reset. Early data from 45 participants, who had all lost at least 15% of their body weight on tirzepatide, shows promise.

Six months after stopping the drug, the 16 participants who received a sham procedure regained about 40% more weight than the 29 who got the real treatment. Those with more extensive resurfacing kept over 80% of their weight loss, regaining only about 7 pounds on average, compared to roughly double that in the control group. Notably, the benefit gap widened over time.

"What's particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response," Dr. Sullivan said, suggesting they're "targeting the right biology." The procedure reportedly has a quick recovery, with most patients back to normal in about a day, and no serious complications were reported in this cohort.

The logic targets the source: the small intestine produces many hormones affected by GLP-1 drugs. Diets high in fat and sugar can damage the duodenal lining, contributing to metabolic issues. By restoring this lining, the procedure aims to reset the body's response to food. The larger REMAIN-1 study, with over 300 participants, is fully enrolled, with topline data expected in early Q4 2026.